Table 2. Risk of lung cancer in statin users and nonusers in the study cohort.
| Entire cohort (n = 43,802) | Patients not using statins (Total follow-up: 194,933.6 person-years) | Patients using statins (Total follow-up: 80,239.4 person-years) | aHR† (95% CI) | ||
|---|---|---|---|---|---|
| No. of patients with lung cancer | Incidence rate (per 105 person-years) (95% CI) | No. of patients with lung cancer | Incidence rate (per 105 person-years) (95% CI) | ||
| Entire cohort | 1225 | 628.4 (593.2, 663.6) | 159 | 198.2 (167.4, 229.0) | 0.37 (0.31, 0.44)*** |
| Age, 40–64 yearsa | 419 | 360.5 (326.0, 395.0) | 66 | 130.8 (99.2, 162.3) | 0.37 (0.29, 0.49)*** |
| Age, 65–74 yearsb | 415 | 930.2 (840.7, 1019.7) | 56 | 257.1 (189.8, 324.5) | 0.31 (0.23, 0.41)*** |
| Age, ≥ 75 yearsc | 391 | 1146.9 (1033.2, 1260.6) | 37 | 463.4 (314.1, 612.7) | 0.43 (0.31, 0.61)*** |
| Femaled | 361 | 413.1 (370.5, 455.7) | 57 | 136.3 (100.9, 171.6) | 0.34 (0.25, 0.45)*** |
| Malee | 864 | 803.4 (749.8, 857.0) | 102 | 265.6 (214.0, 317.1) | 0.39 (0.32, 0.48)*** |
Total follow-up 116,228.5 person-year for patients not using statins and 50,476.0 for patients using statins.
Total follow-up 44,612.9 person-year for patients not using statins and 21,778.3 for patients using statins.
Total follow-up 34,092.2 person-year for patients not using statins and 7,985.1 for patients using statins.
Total follow-up 87,389.9 person-year for patients not using statins and 41,828.7 for patients using statins.
Total follow-up 107,543.7 person-year for patients not using statins and 38,410.7 for patients using statins.
CI: confidence interval.
aHR: adjusted hazard ratio.
Main model was adjusted using propensity scores for age, sex, Charlson comorbidity index, diabetes, hypertension, dyslipidemia, urbanization level, and monthly income.